News & Events

First Patient Treated in Phase I/II CYStem Clinical Trial in Nephropathic Cystinosis

In a community statement issued by Novartis on July 24, 2026: Dear Cystinosis Community, We are pleased to share...

By Cystinosis Research Network

July 24, 2026

A newly approved eye drop solution will expand treatment options for people living with cystinosis in Canada. Targeting corneal...

By Cystinosis Research Network

April 16, 2026

The Cystinosis Research Network (CRN) is pleased to welcome two newly appointed leaders whose professional expertise, lived experience, and...

By Cystinosis Research Network

January 14, 2026

News from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...

The next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...

The Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...

Emory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...

A new chapter in cystinosis research has begun. Novartis has officially opened the next phase of its CYStem Phase...

For our families using Cystadrops, we received the following information from Recordati. This update was in response to direct...